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Abstract
Aims/hypothesis We aimed to report current rates of CVD in type 1 diabetes and to develop a CVD risk prediction tool for type 1
diabetes.
Methods A cohort of 27,527 people with type 1 diabetes without prior CVD was derived from the national register in Scotland.
Incident CVD events during 199,552 person-years of follow-up were ascertained using hospital admissions and death registers. A
Poisson regression model of CVDwas developed and then validated in the Swedish National Diabetes Register (n = 33,183). We
compared the percentage with a high 10 year CVD risk (i.e., ≥10%) using the model with the percentage eligible for statins using
current guidelines by age.
Results The age-standardised rate of CVD per 100,000 person-years was 4070 and 3429 in men and women, respectively, with
type 1 diabetes in Scotland, and 4014 and 3956 in men and women in Sweden. The final model was well calibrated (Hosmer–
Lemeshow test p > 0.05) and included a further 22 terms over a base model of age, sex and diabetes duration (C statistic 0.82;
95% CI 0.81, 0.83). The model increased the base model C statistic from 0.66 to 0.80, from 0.60 to 0.75 and from 0.62 to 0.68 in
those aged <40, 40–59 and ≥ 60 years, respectively (all p values <0.005). The model required minimal calibration in Sweden and
had a C statistic of 0.85. Under current guidelines, >90% of those aged 20–39 years and 100% of those ≥40 years with type 1
diabetes were eligible for statins, but it was not until age 65 upwards that 100% had a modelled risk of CVD ≥10% in 10 years.
Conclusions/interpretation Aprediction tool such as that developed here can provide individualised risk predictions. This 10 year
CVD risk prediction tool could facilitate patient discussions regarding appropriate statin prescribing. Apart from 10 year risk,
such discussions may also consider longer-term CVD risk, the potential for greater benefits from early vs later statin intervention,
the potential impact on quality of life of an early CVD event and evidence on safety, all of which could influence treatment
decisions, particularly in younger people with type 1 diabetes.
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Introduction
In people with type 1 diabetes CVD is a major cause of loss of
life expectancy [1] and CVD risk is elevated two- to fourfold
[2, 3]. CVD risk assessment tools can aid the identification of
individuals who would benefit from preventive treatments, for
guiding decisions on intensification of therapies, and can
improve risk communication to patients. In the general popu-
lation, treatment guidelines allocate treatment to those
reaching various risk thresholds using such tools. For exam-
ple, in the UK the National Institute for Health and Care
Excellence (NICE) recommends using the QRISK2 or
QRISK3 (ClinRisk, UK) risk score [4, 5] to assign statin treat-
ment to those with ≥10% 10 year risk of CVD [6]. For those
with type 1 diabetes, however, crude rule-based algorithms are
used [6, 7]. For example, the UK NICE guidelines recom-
mend statins in all those with type 1 diabetes aged ≥40 years
or those ≥20 years with at least one additional CVD risk factor
[6]. The most recent ESC/EASD guidelines designate all with
type 1 diabetes as being at ‘high risk’ of CVD and warranting
statin with the exception of those below age 35 years and with
diabetes duration <10 years and without other risk factors [8].
Since data on contemporaneous risks of CVD in type 1 diabe-
tes are lacking, it is not clear what risk threshold current guide-
lines are implicitly using in type 1 diabetes. Furthermore, such
rule-based algorithms ignore substantial variation in risk that
might be predictable; accordingly, the development of a CVD
risk score in type 1 diabetes has been called for [7].
Although there are two published tools that might be
used [5, 9], they have not been widely adopted or
promoted in the most recent guidelines [8]. This may
be because neither has had international validation [5,
9], or because quantification of how such tools assign
risks compared with rule-based algorithms is needed to
convincingly demonstrate their utility.
Therefore, using data from the Scottish and Swedish
national diabetes registers, we aimed to: (1) provide contem-
porary data on rates of CVD in people with type 1 diabetes; (2)
develop and internationally validate a CVD risk prediction
model for first CVD events in people with type 1 diabetes;
(3) compare its performance with the two tools previously
reported for first events; and (4) compare the percentage with
various thresholds for 10 year CVD risk using the model with
the percentage eligible for statins using the NICE guidelines.
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Methods
Study design and data sources
Scottish cohort The cohort was formed using a 2019 extract
from the previously described Scottish Care Information –
Diabetes (SCI-Diabetes) dataset [2]. Briefly, since 2004
SCI-Diabetes has collated demographic and clinical data,
including issued prescriptions and retinopathy screening data,
for over 99% of people nationally with an assigned diagnosis
of diabetes. The cohort for this study consisted of adults aged
18 years and above who were diagnosed with type 1 diabetes
below 50 years. Those with a previous CVD event were omit-
ted. The study started on 1 January 2008 and ended on 1
January 2018. Each person’s entry date was defined as the
latest of study start date, date of diabetes diagnosis, date of
18th birthday or date of first coming under observation with
diabetes in the national register. The exit date was defined as
the earliest of study end date, date of death, date of incident
CVD event or ceasing to be under observation in the national
register. CVD outcome data were acquired through linkage to
the Scottish Morbidity Records, the National Health Service
admissions dataset and the death registrations held by the
General Register Office for Scotland. CVD was defined as
any hospital admission or death due to myocardial infarction,
stroke, unstable angina, transient ischaemic attack or periph-
eral vascular disease; or any coronary, carotid or peripheral
artery revascularisations; or major amputation procedures; or
any death due to these conditions; or acute coronary heart
disease. See the electronic supplementary material (ESM)
Methods for the International Classification of Disease
version 10 codes and Office of Population Censuses and
Surveys Classification of Interventions and Procedures
(OPCS-4) codes within this definition.
Candidate covariates Factors reported in the literature as
predicting CVD risk in type 1 diabetes or included in previous
risk models for CVDwere included as covariates for selection
[4, 10] and are listed in ESM Table 1. These were derived
from SCI-Diabetes and linked datasets including prescribing
data. Baseline measurements were those nearest to and prior to
the time of study entry but no more than 24 months before
study entry. We included a covariate for the mean HbA1c in
the preceding 3 years. Measurements were defined at baseline
apart from current age which was time-updated at the begin-
ning of each person-time interval. Covariates with 60% or
more missingness were excluded from the analyses. See the
ESM Methods for further details on covariate definition.
External validation cohort The external validation cohort was
from the Swedish National Diabetes Register (NDR), which
has nationwide coverage, and to which trained clinicians
report clinical information [10]. This registry was initiated in
1996 and includes data for almost all people with type 1
diabetes aged over 18 years. The study start and end dates
for this cohort were 1 January 2002 and 31 December 2013,
respectively. CVD event data were obtained by linkage to the
Swedish Inpatient Register and Cause of Death registries.
Risk factors were defined as for Scotland, except that depri-
vation was measured using quintiles of disposable income.
Statistical analyses
Age-standardised incidence rates for CVD by sex were esti-
mated by direct standardisation to the 2013 European
Standard Population [11]. Missing covariate data in both
cohorts were imputed using multiple imputation using an
expectation–maximisation with bootstrapping (EMB) algo-
rithm, assuming data were missing at random and agnostic
to the CVD outcome, implemented in the Amelia II package
in R [12, 13]. Ten multiply imputed datasets were created and
for continuous variables the mean of the imputed values was
used in the regression model. Categorical variables were
converted to probabilities for each category, reflecting the
frequency of each category across the ten imputations.
For model derivation, within the Scottish cohort, person-
time was split into 1 year intervals, with each observation
constituting a 1 year person-time interval. A base model
including the baseline and time-updated age, sex and baseline
diabetes duration and an offset term for intervals in which
censoring occurred was generated first using Poisson regres-
sion using the R package glm. Forward selection was then
used to add risk factors to the model as long as the Akaike
information criterion fell by at least the number of extra
parameters (i.e., with the k = 3 setting in the R package step).
Covariates with a skewed distribution (eGFR, total
cholesterol:HDL-cholesterol ratio and BMI) were log trans-
formed. Quadratic and cubic terms were entered for age, since
we know a priori that the relationship with CVD is likely non-
linear. Interactions between each candidate covariate and age
and sex were considered for inclusion in the model. The
cumulative survival free of CVD by any given attained age,
conditional on not otherwise being censored, was generated
using the current age- and sex-specific average survival prob-
abilities generated by the Poisson model. Survival probabili-
ties were obtained using the predict function in R. See the
ESM Methods for model sensitivity checks.
Predictive performance was examined in a 20-fold training
test cross-validation framework. The dataset was partitioned
into 20 disjoint test sets each comprising 5% of the study
population. For each test set the remaining 95% of the popu-
lation constituted the training set. The modelling process was
then run on each training set and the resultant model was
applied to its test set, thus yielding predicted values for that
test set. The 20 test sets each with an observed and predicted
value for each individual in that test set were concatenated into
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a single dataset that was used to evaluate predictive perfor-
mance. Using this combined test dataset, the increment in
discrimination achieved with the final model compared with
the base model was quantified using the C statistic and the
expected information for discrimination, Λ, which is
expressed in bits [14]. Increments in Λ are interpretable in
absolute units whereas increments in C statistic are not. Λ
was computed with the R package wevid [15]. The pROC
package was used to compute the C statistic as the area under
the receiver operating characteristic (ROC) curve, using the
trapezoidal rule equivalent to Harrell’s C statistic. The
strength of evidence that the final model improved the predic-
tive performance on top of the base model was assessed by the
increment in test log-likelihood; a difference in test log-
likelihood of 6.9 natural log units is asymptotically equivalent
to a p value less than 0.005 for comparison of nested models
[16]. Calibration was assessed visually using calibration plots
and by testing whether the observed and predicted counts of
events differed significantly across deciles of risk using the
Hosmer–Lemeshow test. See the ESM Methods for special
considerations on evaluating predictive performance from
survival models that informed the evaluation. For external
validation in the Swedish cohort, the model was first re-
calibrated by setting the intercept so as to equate the total
observed and predicted events, since we expect a priori that
incidence rates will differ between countries, and the predic-
tive performance was then evaluated as above (see the ESM
Methods for further details).
In the Scottish cohort we calculated the percentage of indi-
viduals in Scotland who would receive statins under the NICE
guidelines, i.e., those with age ≥ 40 years or having diabetes
for more than 10 years or having established nephropathy or at
least one other CVD-related risk factor by age band. Using the
model, we calculated the percentage in each age band in
Scotland that had a 10 year predicted risk of CVD of ≥10%
and also of ≥5%. For the purpose of this calculation, the
predicted risk of all those on a statin already at baseline was
increased by 25% to account crudely for the typical reduction
in risk expected with statin therapy.
We applied risk equations from the Steno CVD Type 1
Engine and the QRISK3 model to the Scottish dataset and
compared the resultant expected with observed events and
calculated the C statistic using the pROC package.
Results
Age-standardised rates of CVD in Scotland and
Sweden
Overall, 27,527 individuals with type 1 diabetes were included
in the final cohort in Scotland following the exclusion of 1952
individuals with a previous history of CVD. There were 2790
CVD events during 199,552 person-years of follow-up. Of first
events, 51% were coronary, 11% cerebrovascular or carotid,
and 38% peripheral vascular. Baseline characteristics of those
developing vs not developing CVD are shown in ESMTable 1.
The Swedish cohort included 33,183 people in whom there
were 3262 incident CVD events during 253,197 person-years
of follow-up. The confidence intervals for the sex-specific
age-standardised rates overlapped in Scotland and Sweden
and rates were <600/100,000 person-years at age 18–39 in
both (Table 1).
Model development and performance in the Scottish
dataset
Most covariates had less than 20% missingness (ESM Table 2).
For most of the risk factors of interest adjusted for age, sex and
diabetes duration there were statistically significant associations
with CVD (ESM Table 3). Using forward selection, the final
model included 22 risk factor terms, including quadratic and
cubic terms for current age and interaction terms (Table 2).
The final model increased the model C statistic compared with
the baseline model in all age–sex strata (Table 3). Using Λ, the
improvement in predictive performance was greatest in the
youngest age band (Table 3). The increment in test log-
likelihood of the model compared with baseline was sufficiently
large in all age–sex strata to be statistically significant
(p < 0.005). The model was well calibrated, with a Hosmer–
Lemeshow test result that was non-significant at p = 0.7 (Fig. 1).
External validation in the Swedish cohort
See ESM Table 4 for characteristics, ESM Table 5 for
missingness and ESM Table 6 for risk factor associations in
Sweden. To recalibrate the model, a recalibration factor γ of
0.06 was required to achieve calibration (ESM Fig. 1). This
effectively reflects a 6% higher average risk in the Swedish
data. As shown in Table 3, the increment in test log-likelihood
shows that the model significantly improved prediction of
CVD in Sweden in all age bands and in both sexes (all differ-
ences were at least 20 natural log units, p < 0.005) beyond the
base model. The overall C statistic increased from 0.80 for the
base model to 0.85 for the final model. The increment in
prediction was greatest in the youngest age band (increment
inΛ of 0.69 bits of information) and was similar in both sexes.
Use of the model and web application
The final model intercept and coefficients are given in Table 4.
Instructions for use are given in the ESM Results. A web-
based Shiny application implementing the final model is avail-
able at: https://diabepi.shinyapps.io/cvdrisk/. This is for
illustrative purposes only as a tool for clinical use would
require device approval before use in many countries.
Diabetologia
Comparison of performance with previously
published risk scores
When applied to the Scottish dataset, discriminative perfor-
mance of the Steno model was similar and the QRISK3 much
lower than for the model we developed in Scotland (ESM
Table 7). The Steno model substantially overestimated
predicted events and the QRISK3 model substantially
underpredicted events in Scotland.
Proportions eligible for statin therapy using NICE
guidelines and the proportions exceeding 10% and
5% 10 year risk thresholds
If the NICE 2016 guidelines were applied in practice, then
100% of those with type 1 diabetes without prior CVD would
be prescribed statin from age 40 years, with 81–90% being
assigned statin from age bands in the 20–40 year range (ESM
Table 8). However, the percentage with a 10 year risk ≥10%
does not near 100% until age band 65–70 years, even allowing
for statin effects on risks. The percentage with a 10 year risk of
CVD ≥5% reaches 100% by age 55 years (ESM Table 8).
Cumulative survival free of CVD
Figure 2 shows that about 80% of women and men would be
expected to remain free of CVD by age 50, but just 50%
remain free of CVD by age 65 in men and 67.5 in women if
current age-specific risks are applied across the life course.
Alternative model without a socioeconomic indicator
For countries without a socioeconomic indicator, using the
same process we produced an alternative model omitting
Scottish Index of Multiple Deprivation (SIMD) from the
forward selection (ESM Table 9) which had a slightly lower
performance (Λ of 1.19 vs 1.22).
Discussion
Current rates of CVD in type 1 diabetes
We have shown broadly similar current age-standardised inci-
dence rates of CVD between the Scottish and Swedish datasets
for the group of events studied, with low rates in those below age
40 in both countries. The cumulative survival curve shows that at
current disease rates 80% remain free of CVD by age 50 years.
Thus, current guidelines that labelmost younger peoplewith type
1 diabetes as being a high-risk group could create an erroneous
impression of the risk of CVD unless the timeframe is appropri-
ately specified. On the other hand, it can be seen that incidence
rises steeply with age such that by their mid-sixties about half of
those with type 1 diabetes will have developed CVD.
This study is by far the largest recent study of CVD rates in
type 1 diabetes and the first to show rates for two whole
countries. Direct comparison with other smaller studies is
made difficult because of the varying specifications of clinical
events and the uncertainty in representativeness of clinic-
based populations for the background population being stud-
ied. In the Steno Diabetes Centre study for the years 2001–
2013, the crude overall reported rate was much higher than
ours at 27/1000 person-years [9], but, for the same period, the
validation cohort from a different part of Denmark had an
event rate much nearer ours at 17/1000 person-years. The
Pittsburgh Epidemiology Data Center (EDC) reported higher
CVD rates than in our cohort, though the wide confidence
intervals in that study overlap ours in these age bands [17].
A previous analysis of primary care records in the UK
described lower incidence rates than here [18], but did not
include unstable angina or peripheral vascular disease.
Table 1 Age-standardised CVD rates in Scotland and Sweden
Sex Age N events Follow-up (person-years) Age-standardised rate (95% CI)
Scotland Sweden Scotland Sweden Scotland Sweden
Male 18–39 379 349 65,795.59 92,567.20 599 (540, 662) 472 (432, 514)
40–59 937 1047 42,013.01 38,756.81 2491 (2324, 2668) 3015 (2830, 3209)
60–95 342 405 5,612.36 5664.05 9995 (7320, 14,041) 9478 (7520, 12,909)
Female 18–39 281 272 49,971.22 76,465.07 598 (530, 673) 372 (329, 420)
40–59 564 772 30,681.44 33,738.62 1995 (1826, 2178) 2435 (2263, 2617)
60–95 287 417 5478.82 6005.46 8417 (6370, 11,263) 9952 (7980, 12,846)
Male All 1658 1801 113,420.95 136,988.06 4070 (3240, 5285) 4014 (3406, 5046)
Female All 1132 1461 86,131.48 116,209.15 3429 (2793, 4285) 3956 (3346, 4829)
Event rates are per 100,000 person-years, age standardised to the 2013 European Standard Population
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Risk prediction model
We have developed and internally validated a well-calibrated
risk prediction model with good discriminative performance.
We have shown that in Sweden the model was good at
discrimination and little recalibration was required. Our
development and validation cohorts were large, with altogeth-
er 7767 CVD events. Previously, a tool was developed with
just 95 events [19] in the EURODIAB Prospective
Complications Study, and another from Sweden included both
primary and secondary events (n = 197) [20], and neither of
these has been widely adopted. The QRISK3 model
Table 2 Final multivariable
Poisson model regression results Predictor IRR (95% CI) p value
Age at entry (years) 0.967 (0.954, 0.980) <0.001
Current age (years) 1.384 (1.279, 1.497) <0.001
Current age2 (years2) 0.996 (0.995, 0.998) <0.001
Current age3 (years3) 1.000 (1.000, 1.000) <0.001
Sex
Male 1 (reference)
Female 0.402 (0.277, 0.583) <0.001
Diabetes duration (years at entry) 1.020 (1.017, 1.024) <0.001
Deprivation index
Quintile 1 (most deprived) 1 (reference)
Quintile 2 0.893 (0.800, 0.996) 0.043
Quintile 3 0.751 (0.667, 0.845) <0.001
Quintile 4 0.680 (0.600, 0.771) <0.001
Quintile 5 (least deprived) 0.572 (0.499, 0.657) <0.001
HbA1c (mmol/mol) 1.011 (1.001, 1.021) 0.029
Mean HbA1c (last 3 years) (mmol/mol) 1.027 (1.015, 1.040) <0.001
log BMI (kg/m2) 0.146 (0.058, 0.368) <0.001
Height (m) 0.058 (0.019, 0.178) <0.001
Weight (kg) 1.008 (0.993, 1.024) 0.304
Systolic BP (mmHg) 1.004 (1.002, 1.007) 0.001
log total cholesterol:HDL-cholesterol ratio (mmol/l) 1.641 (1.405, 1.917) <0.001
log eGFR (ml min−1 1.73 m−2) 0.706 (0.595, 0.837) <0.001
Albuminuric grade
Normal 1 (reference)
Macro 2.505 (2.129, 2.948) <0.001
Micro 1.407 (1.268, 1.561) <0.001
Retinopathy grading
No retinopathy 1 (reference)
Non-referable 1.103 (0.982, 1.239) 0.097
Referable or eye clinic 1.502 (1.341, 1.683) <0.001
Tobacco smoking
Never smoked 1 (reference)
Ever smoked 1.405 (1.289, 1.531) <0.001
Treated for hypertension 1.357 (1.236, 1.489) <0.001
Treated for dyslipidaemia 1.150 (1.045, 1.267) 0.004
Ever atrial fibrillation 1.857 (1.181, 2.919) 0.007
Interaction: Age × 3 year mean HbA1c 1.000 (1.000, 1.000) <0.001
Interaction: Age × weight 1.000 (1.000, 1.000) 0.016
Interaction: Sex × HbA1c 1.003 (1.000, 1.007) 0.079
Interaction: Sex × log total cholesterol:HDL-cholesterol ratio 1.481 (1.168, 1.879) 0.001
Normal albuminuria is an albumin/creatinine ratio < 30, micro is 30–300 and macro is >300 mg/l
IRR, incidence rate ratio
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developed in the general primary care population in England
had poor predictive performance in our data partly because it
contains many variables that are only captured routinely in
settings using the primary care software used in its develop-
ment cohort. Here, we have provided international validation
with the Steno Diabetes Centre score based on a much smaller
cohort with 793 events [9]. It showed similar discrimination in
our population to our own model, but substantial recalibration
would be needed to apply it in our population or in Sweden as
it overestimated risks by about 27%.
Potential utility of the model in clinical decision
making
We have shown that current algorithmic approaches for statin
therapy initiation in type 1 diabetes using the NICE guidelines
assign everyone aged 40 and over, and more than 90% of
those aged 20 and over, to statin therapy. The recent
European Societies’ guidelines assign more to statin therapy
than the NICE guideline and label most adults with type 1
diabetes as being at ‘high risk’ for CVD. For the general
population NICE uses a 10 year risk threshold for allocating
statins, but the majority of those younger people with type 1
diabetes eligible for statins using the NICE guideline do not
have risks of this level. Our purpose in making this compari-
son is not to advocate for altering guidelines to reduce eligi-
bility for statins in type 1 diabetes. Rather, it is to stimulate
discussion about the reasoning behind different guidelines and
to enable future guidelines to be informed by current rather
than out-of-date assumptions about absolute risks. Guideline
committees, clinicians and people with diabetes might consid-
er that for a given absolute 10 year risk level there is a ratio-
nale for being more assertive in introducing preventive thera-
pies in type 1 diabetes than in the general population. If so, the
rationale should be made explicit.
Arguments in favour of more assertive therapy at a given
absolute 10 year risk in type 1 diabetes might include consid-
erations of lifetime risk and of the loss of quality-adjusted life
years from very early CVD events. Other justifications for
introducing lipid-lowering therapy earlier in life and at lower
absolute 10 year risk thresholds have been elegantly argued
elsewhere [21]. The arguments include the dramatic effects of
genetic mutations that lower LDL-cholesterol from early life
on CVD risks, meta-analyses that found lower relative risk
reductions at older than younger ages with statins and the lack
of any evidence of diminution in effect of statins with longer-
term use. Also relevant is that cost effectiveness of statin ther-
apy at population level down to a 5% 10 year risk has been
demonstrated [22], as well as the excellent safety profile of
statin therapy. These arguments have to be balanced against
the lack of trial evidence so far that introducing statins at age
20 will alter the rate at age 50 any more than introducing
statins at, say, 45 years of age. Also for consideration is the
lack of data on very long-term statin safety. Most vital is the
need to avoid labelling young people with type 1 diabetes as
being at high short-term risk of CVD if they are not, and to
reassure when treatments are being based on long-term risks,
or other considerations discussed above. To this end, we hope
Table 3 Increment in the prediction of incident CVD from the base model to the final model in Scottish and Swedish validation datasetsa
Group C statistic (base) (95% CI) C statistic (final) (95% CI) Λ (base) Λ (final) log-likelihood increment
(natural log units)
Scotland
All 0.75 (0.74, 0.76) 0.82 (0.81, 0.83) 0.62 1.22 868.43
Male 0.76 (0.75, 0.77) 0.81 (0.80, 0.82) 0.61 1.18 439.33
Female 0.74 (0.73, 0.76) 0.83 (0.82, 0.84) 0.61 1.26 429.10
20–39 0.66 (0.64, 0.69) 0.80 (0.78, 0.82) 0.16 0.97 201.59
40–59 0.60 (0.59, 0.62) 0.75 (0.74, 0.76) 0.11 0.60 533.91
60+ 0.62 (0.60, 0.64) 0.68 (0.67, 0.70) 0.15 0.38 125.63
Sweden
All 0.80 (0.80, 0.81) 0.85 (0.85, 0.86) 0.91 1.64 211.10
Male 0.80 (0.80, 0.82) 0.85 (0.84, 0.86) 0.90 1.64 71.57
Female 0.80 (0.80, 0.82) 0.85 (0.85, 0.86) 0.91 1.65 515.27
20–39 0.72 (0.70, 0.75) 0.82 (0.79, 0.84) 0.48 1.17 802.65
40–59 0.66 (0.65, 0.67) 0.75 (0.74, 0.76) 0.23 0.70 434.05
60+ 0.61 (0.60, 0.63) 0.66 (0.65, 0.67) 0.11 0.32 368.60
An increment in the test log-likelihood ≥6.9 natural log units is asymptotically equivalent to a p value <0.005, therefore all results are highly significant
Information for discrimination Λ is measured in bits
a Base is the base model adjusted for age, sex and duration. Final is the final model including all covariates selected by forward selection and detailed in
the Poisson regression output
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that the data and prediction tool we provide will be helpful to
guideline committees and will facilitate conversations and
decision making between clinicians and people with type 1
diabetes about when and why to start preventive therapies. For
example, the model could be used in those below age 50 to
detect those at high 10 year risk and ensure prevention strate-
gies are maximised but also to reassure others with lower
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Fig. 1 (a–f) Calibration of the model in the Scottish cross-validation test
dataset overall and by sex and age band. (a) All (199,552 person-years).
(b) Female (86,131 person-years). (c) Male (113,421 person-years). (d)
Age at entry 20–39 years (89,089 person-years). (e) Age at entry 40–
59 years (73,005 person-years). (f) Age at entry ≥60 years (11,197
person-years)
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for discrimination of risk as our own model, but it
overestimated risk in our population.
Ten year risk vs lifetime risk
The 2016 European Societies’ guideline explicitly recom-
mends using 10 year risk, as we have done, rather than lifetime
risk [7]. Lifetime estimates either make the incorrect assump-
tion that current age-specific incidence rates will not change in
the future or they make various untestable assumptions about
how rates will change. Nonetheless, we provide the best avail-
able estimates of the cumulative probability of survival free of
CVD by attained age derived from current age-specific rates
as in Fig. 2. Note that when we show that the probability of
being free of CVD by one’s mid-sixties is 50%, for a 20 year
old today the true probability is very likely to be much higher
than this in 40 years’ time if current calendar time trends of
decreasing CVD rates in developed economies continue. We
consider that it is better to be explicit about where uncer-
tainties lie in presenting risks, and lifetime risk estimates will
always carry substantial uncertainty.
Study strengths and limitations
Strengths of our study are: (1) the complete coverage of the
population and much larger dataset than for many studies of
Table 4 Predictor variables and
coefficients for risk prediction of
CVD in type 1 diabetes
Predictor Coefficient
(Intercept) −4.03403744
Current age (years) 0.32483759
Current age2 (years2) −0.00389356
Current age3 (years3) 1.993×10−5
Sex male 0.00000000
Sex female −0.91153788
Diabetes duration (years) 0.0201993
Deprivation quintile 1 (most deprived) 0.00000000
Deprivation quintile 2 −0.11366821
Deprivation quintile 3 −0.28641292
Deprivation quintile 4 −0.38497544
Deprivation quintile 5 (least deprived) −0.55777639
HbA1c (mmol/mol) 0.01071311
Mean HbA1c (last 3 years) (mmol/mol) 0.02712284
log BMI (kg/m2) −1.9247447
Height (m) −2.84393889
Weight (kg) 0.00802065
Systolic BP (mmHg) 0.0041725
log total cholesterol:HDL-cholesterol ratio (mmol/l) 0.49545924
log eGFR (ml min−1 1.73 m−2) −0.34828245
Albuminuric grade normal 0.00000000
Albuminuric grade micro 0.34128044
Albuminuric grade macro 0.91835596
Retinopathy none 0.00000000
Retinopathy non-referable 0.09832872
Retinopathy referable or eye clinic 0.40705123
Never smoked 0.00000000
Tobacco smoking 0.34002647
Treated for hypertension 0.30504081
Treated for dyslipidaemia 0.14012891
Ever atrial fibrillation 0.61882651
Interaction: Sex × log total cholesterol:HDL-cholesterol ratio 0.39282042
Interaction: Age × weight 0.00023665
Interaction: Sex × HbA1c 0.00335224
Diabetologia
CVD in type 1 diabetes; (2) the provision of up-to-date abso-
lute rates of events; (3) the use of statistical methods that avoid
overfitting; and (4) the external validation in the Swedish
NDR register. Limitations are that both our development and
validation cohorts are European. Also, competing risks may
mean that the absolute risk of CVD estimated by the model
could be inflated where competing risks are common such as
in the elderly, and use of the model in older individuals should
take this into consideration. However, the envisaged utility of
the model is more for risk prediction in younger individuals.
As with all prediction models, prediction in different countries
is optimised if there are available data to allow recalibration to
reflect between-country differences in overall rates. We found
only a slight recalibration was needed to reflect a slightly
higher risk in the Swedish data, which is likely to reflect the
earlier time period of coverage of the Swedish than Scottish
data. Furthermore, different countries will need to substitute
an equivalent socioeconomic indicator for the SIMD variable.
For countries with no such indicator available we have provid-
ed an alternative model that does not use a socioeconomic
indicator. Incidence and prevalence estimates will vary with
the exact definition of CVDused. Our CVD outcome included
both fatal and non-fatal CVD events, but to enhance specific-
ity all the non-fatal events were hospital verified. By compar-
ison, in the QRISK3 risk score derivation cohorts, more than
50% of all events were non-hospitalised events, including
transient ischaemic attacks which are frequently false positive
diagnoses [5, 22]. In contrast, the 2016 European Societies’
guideline Systematic Coronary Risk Evaluation (SCORE) risk
charts focus only on fatal events on the basis that there is too
much diagnostic variation between countries in non-fatal
events [7]. Finally, we note that predictors from routinely
collected clinical data will likely have a lower model
performance than those collected in an idealised standardised
setting. However, this will be a more realistic reflection of the
performance in a real-world clinical setting.
Conclusions
In conclusion, absolute rates of CVD in type 1 diabetes at
younger ages are now lower than most international guide-
lines implicitly assume. Many people with type 1 diabetes
below age 50 are not at high 10 year risk of CVD and should
not be labelled as such. The contemporary data on risks of
disease, and the provision of a risk prediction tool as presented
here, could facilitate decision making on when and in whom
to initiate CVD preventive therapies in type 1 diabetes. Such
decisions may need to be made on a wider set of consider-
ations than absolute 10 year risk alone.
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